Selective Estrogen Receptor Modulators (SERMs) for prevention and treatment of postmenopausal osteoporosis;Selektive Östrogen-Rezeptormodulatoren (SERMs) zur prävention und therapie der postmenopausalen osteoporose

Therapeutische Umschau

Volumn 69, Issue 3, 2012, Pages 163-172

  Birkhäuser, Martin ^a  

^a UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; ESTROGEN RECEPTOR; HORMONE; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CLIMACTERIUM; DRUG APPROVAL; DRUG INDICATION; DRUG SAFETY; EUROPE; EUROPEAN UNION; FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROPHYLAXIS; RISK REDUCTION; SWITZERLAND; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPINAL FRACTURES;

EID: 84857935021     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000269     Document Type: Article

References (44)

1. Nilsson S and Gustafsson J-Å. Estrogen Receptors: Therapies Targeted to Receptor Subtypes. Clinical pharmacology & Therapeutics 2011; 89: 44-55.
2. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci. 2001 Dec; 949: 317-26.
3. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-645.
4. Martino S et al. Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene. J Natl Cancer Inst 2004; 96: 1751-1761.
5. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.
6. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-41.
7. Goldstein SR et al.: Raloxifene use in clinical practice: efficacy and safety. Menopause 2009; 16: 413-421.
8. Johnston C et al.: Long-term effects of raloxifene on bone mineral density, bone turnover and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo- controlled trials. Arch Intern Med 2000; 160: 3444-50.
9. Delmas P, Bjarnason N, Mitlak B, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7.
10. Jolly E et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10: 337-344.
11. Qu Y, Wong M, Thiebaud D, Stock JL. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin 2005; 21: 1955-1959.
12. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162: 1140-1143.
13. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609-3617.
14. Kanis JA Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 2003; 33: 293-300.
15. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Anti-vertebral fracture efficacy of raloxifene: a metaanalysis. Osteoporos Int 2006; 17: 313-6.
16. Kanis JA, Johansson H, Oden A, Mc-Closkey EV. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral frac fractures and its dependency on FRAX. Bone 2010; 47: 729-35.
17. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003: 33: 522-532.
18. DeMichele A, Troxel AB, Berlin JA, Weber AL, Bunin GR, Turzo E, Schinnar R, Burgh D, Berlin M, Rubin SC, Rebbeck TR, Strom BL 2008 Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population- based case-control study. J Clin Oncol 26: 4151-4159.
19. Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 2006; 12: 5242-5247.
20. Mosca L, Grady D, Barrett-Connor E, Collins P, Wenger N, Abramson BL, Paganini-Hill A, Geiger MJ, Dowsett SA, Amewou-Atisso M, Kornitzer M. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009; 40: 147-55.
21. Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D 2009 Raloxifene and risk for stroke based on the Framingham Stroke Risk Score. Am J Med 122: 754-761.
22. Cranney A, Adachi JD 2005 Benefitrisk assessment of raloxifene in postmenopausal osteoporosis. Drug Safety 28: 721-730.
23. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R; PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362: 686-96 Erratum in: N Engl J Med 2011; 364: 290.
24. Gennari L. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Expert Opin Pharmacother. 2009; 10: 2209-2220.
25. Miller P et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, doubleblind, placebo-, and active-controlled study. J Bone Miner Res 2008; 23: 525-535.
26. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008; 23: 1923-34.
27. Kanis JA, Johansson H, Oden A, Mc-Closkey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009; 44: 1049-54.
28. Archer DF et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009; 16: 1109-1115.
29. Christiansen C, Chesnut CH 3rd, Adachi JD, Brown JP, Fernandes CE, Kung AW, Palacios S, Levine AB, Chines AA, Constantine GD. Safety of bazedoxifene in a randomized, double-blind, placebo- and activecontrolled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010; 11: 130.
30. Pickar JH et al. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009; 92: 1018-1024.
31. Lindsay R et al. Efficacy of tissueselective estrogencomplex of bazedoxifene/ conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009; 92: 1045-1052.
32. Lobo RA et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009; 92: 1025-1038.
33. Archer DF et al. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009; 92: 1039-1044.
34. Pinkerton JV et al. Relief of vasomotor symptoms with the tissueselective estrogen complex containing Bazedoxifene/Conjugated Estrogens: a randomized, controlled trial. Menopause 2009; 16: 1116-1124.
35. Gordon S, Walsh BW, Ciaccia AV, et al. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. Obstet Gynecol 2004; 103: 267-73.
36. Davis SR, O'Neill SM, Eden J, et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects of treatment satisfaction and the endometrium - a pilot study. Menopause 2004; 11: 167-75.
37. Cauley JA, Robbims J, Chen Z et al. for the Women's Health Initiative Investigators. Effects of Estrogens Plus Progestins on Risk of Fracture and Bone Mineral Density. JAMA 2003; 290: 1729-1738.
38. Anderson GL, Hutchinson F, Limacher M et al. for the Women's Health Initiative Investigators.Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. JAMA. 2004; 291: 1701-1712.
39. LaCroix AZ, Chlebowski RT, Manson JAE et al. for the WHI Investigators. Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy. JAMA. 2011; 305: 1305-1314.
40. Grady D et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004; 104: 837-44.
41. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005; 20: 1514-24.
42. Cummings SR et al.: The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women, JAMA, 1999; 281: 2189-2197.
43. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to évista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-61.
44. Hadji P, Lippuner K, Concin H, Scharla S, Birkhäuser M, Fahrnleitner A, Finkenstedt G, Jakob FJ, Schwarz H, Stute P, Ziller V. Therapie der Osteoporose: Selektive Östrogenrezeptor-Modulatoren (SERM) und neue Optionen. Mineralstoffwechsel 2012 (in press).